In this article, we look at recent clinical updates from the gene-editing field. These updates include clinical data from Vor Bio's ongoing Phase 1/2a...

Caribou Biosciences has reported positive long-term follow-up data from the dose escalation portion of the ongoing ANTLER Phase 1 trial. The trial is...

In this week's clinical update, we look at recent news from Caribou Biosciences. The company's second gene-edited CAR-T cell therapy candidate,...

Founded in 2011, Caribou Biosciences is developing novel allogeneic CAR-T cell and CAR-natural killer cell therapies to treat cancer. The UC Berkeley...

In recent years, researchers have turned to gene editing to address the limitations of CAR T therapies. This roundup summarises the clinical-stage...

Caribou Biosciences has reported new 12-month clinical data from its ongoing ANTLER Phase 1 trial of CB-010 for relapsed/refractory B cell non-Hodgkin...

In this piece, we bring a summary of the latest clinical data from Editas Medicine's ongoing RUBY trial for EDIT-301 in severe sickle cell disease, as...

This week's clinical update summarises data shared at the recent European Hematology Congress (EHA2022). The updates include positive data from...